BRS & ENT UK welcome NICE recommendation to fund dupilumab for patients with CRSwNP

02 February 2026 (Last updated: 3 Feb 2026 11:11)

The British Rhinological Society (BRS) and ENT UK welcome NICE’s positive recommendation to fund dupilumab for patients with chronic rhinosinusitis with nasal polyps who continue to experience severe symptoms despite previous surgery.

For the majority of patients, effective symptom control is achieved through endoscopic sinus surgery combined with appropriate postoperative medical treatment. This will continue to represent first-line management for patients in whom intranasal medical therapy has not provided adequate control. Where surgery is undertaken, evidence supports the role of appropriately comprehensive endoscopic sinus surgery in delivering more durable outcomes than limited procedures or polypectomy alone. This approach is not altered by the current decision to provide access to dupilumab.

For patients whose disease recurs following surgery, ENT specialists in England and Wales will now be able to discuss both revision surgery and biologic treatment with dupilumab. Each option carries distinct risks and benefits, and this decision should be made through shared decision-making between clinicians and patients. BRS and ENT UK welcome the opportunity to offer patients greater choice in managing severe disease.

Over the coming weeks, the British Rhinological Society, working in collaboration with ENT UK, will support the development of clear clinical guidance to assist specialists and patients in making informed treatment decisions. This represents a significant and positive development for patients with chronic rhinosinusitis with nasal polyps, and both organisations are committed to supporting the timely, appropriate, and equitable introduction of this treatment into clinical practice.